Restricted accessResearch articleFirst published online 2021-8
Relationship Between Treatment Duration and Efficacy of Pharmacological Treatment for ADHD: A Meta-Analysis and Meta-Regression of 87 Randomized Controlled Clinical Trials
Objective: To determine the relationship between treatment duration and the efficacy of pharmacological treatment for reducing ADHD symptoms. Method: We conducted a systematic review of randomized, double-blind, placebo-controlled clinical trials investigating the efficacy of pharmacological interventions in patients with ADHD. The last bibliographic search was performed in April 15, 2019. The effect of treatment duration on efficacy was studied using meta-regression. Results: A total of 87 studies lasting from 3 to 28 weeks were included. Pharmacological treatment improved ADHD symptom severity by −7.35 points. Treatment duration did not moderate the efficacy of pharmacological treatment. Consistent results were found for psychostimulant drugs, methylphenidate, amphetamine derivatives, atomoxetine, and α2-agonists. A negative correlation was found between baseline ADHD severity efficacy (Coefficient = −.250, p = .013). Conclusion: The efficacy of pharmacological treatment for ADHD remains stable over time. A greater efficacy in more severe patients is suggested.
AdlerL.TanakaY.WilliamsD.TrzepaczP. T.GotoT.AllenA. J.. . . UpadhyayaH. P. (2014). Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study. Journal of Clinical Psychopharmacology, 34, 461–466. https://doi.org/10.1097/JCP.0000000000000138
2.
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.).
3.
ArnstenA.F.PliszkaS.R. (2011). Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacology Biochemistry and Behavior, 211–216. doi:10.1016/j.pbb.2011.01.020
4.
BanaschewskiT.BauerM.BeaM.DöpfnerM.GelbM.GrosseK.P.. . . WilkenB. (2018). S3 - Guideline of attention deficit hyperactivity disorder (ADHD) in childhood, adolescence and adulthood [Leitlinie Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter]. Retrieved from https://www.awmf.org/leitlinien/detail/ll/028-045.html
5.
BanaschewskiT.JohnsonM.LecendreuxM.ZuddasA.AdeyiB.HodgkinsP.. . . CoghillD. R. (2014). Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder. CNS Drugs, 28, 1191–1203. https://doi.org/10.1007/s40263-014-0193-z
6.
BarkleyR. A.MurphyK. R.DupaulG. I.BushT. (2002). Driving in young adults with attention deficit hyperactivity disorder: Knowledge, performance, adverse outcomes, and the role of executive functioning. Journal of the International Neuropsychology Society, 8, 655–672.
7.
Beau-LejdstromR.DouglasI.EvansS. J.SmeethL. (2016). Latest trends in ADHD drug prescribing patterns in children in the UK: Prevalence, incidence and persistence. British Medical Journal Open, 6(6), Article e010508. https://doi.org/10.1136/bmjopen-2015-010508
8.
BespalovA.MüllerR.ReloA. L.HudzikT. (2016). Drug tolerance: A known unknown in translational neuroscience. Trends in Pharmacological Sciences, 37, 364–378. https://doi.org/10.1016/j.tips.2016.01.008
9.
BiedermanJ.LopezF. A.BoellnerS. W.ChandlerM. C. (2002). A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics, 110, 258–266.
10.
Bolea-AlamañacB.NuttD. J.AdamouM.AshersonP.BazireS.CoghillD. R., . . . British Association for Psychopharmacology. (2014). Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 28, 179–203.
11.
BorensteinM.HedgesL. V.HigginsJ. P. T.RothsteinH. R. (2013). Comprehensive Meta-Analysis (Version 3.3.070). Biostat.
12.
CamporealeA.UpadhyayaH.Ramos-QuirogaJ. A.WilliamsD.TanakaY.LaneJ. R.EscobarR.TrzepaczP.AllenA. J. (2013). Safety and tolerability of atomoxetine hydrochloride in a long-term, placebo-controlled randomized withdrawal study in European and non-European adults with attention-deficit/hyperactivity disorder. European Journal of Psychiatry, 27, 206–224.
13.
Canadian ADHD Resource Alliance. (2018). Canadian ADHD practice guidelines (4th ed.) [Internet]. http://caddra.ca
14.
CastellsX.Blanco-SilventeL.CunillR. (2018). Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Systematic Reviews, 9(8), Article CD007813.
15.
CastellsX.Ramos-QuirogaJ. A.RigauD.BoschR.NogueiraM.VidalX.CasasM. (2011). Efficacy of methylphenidate efficacy for adults with attention deficit hyperactivity disorder. A meta-regression analysis. CNS Drugs, 25, 157–169.
16.
CharachA.YeungE.ClimansT.LillieE. (2011). Childhood attention-deficit/hyperactivity disorder and future substance use disorders: Comparative meta-analyses. Journal of the American Academy of Child and Adolescent Psychiatry, 50, 9–21.
17.
CoghillD. R.BanaschewskiT.LecendreuxM.JohnsonM.ZuddasA.AndersonC. S.. . . SquiresL. A. (2014). Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: Randomized-withdrawal study design. Journal of the American Academy of Child and Adolescent Psychiatry, 53, 647–657. https://doi.org/10.1016/j.jaac.2014.01.017
18.
CorteseS.AdamoN.Del GiovaneC.Mohr-JensenC.HayesA. J.CarucciS.. . . CiprianiA. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. The Lancet Psychiatry, 5, 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4
19.
CunillR.CastellsX.TobiasA.CapellàD. (2013). Atomoxetine for attention deficit hyperactivity disorder in the adulthood: A meta-analysis and meta-regression. Pharmacoepidemiology and Drug Safety, 22, 961–969.
20.
CunillR.CastellsX.TobiasA.CapellàD. (2016). Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: A meta-analysis and meta-regression in over 9000 patients. Psychopharmacology (Berlin), 233, 187–197.
21.
DaleyD.BirchwoodJ. (2010). ADHD and academic performance: Why does ADHD impact on academic performance and what can be done to support ADHD children in the classroom?Child Care and Health Development, 36, 455–464.
22.
DalsgaardS.ØstergaardS. D.LeckmanJ. F.MortensenP. B.PedersenM. G. (2015). Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: A nationwide cohort study. Lancet, 385, 2190–2196.
EggerM.Davey SmithG.SchneiderM.MinderC. (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal, 315, 629–634. https://doi:10.1136/bmj.315.7109.629
25.
Gupte-SinghK.SinghR. R.LawsonK. A. (2017). Economic burden of attention-deficit/hyperactivity disorder among pediatric patients in the United States. Value in Health, 20, 602–609.
26.
GuyattG. H.OxmanA. D.VistG. E.KunzR.Falck-YterrY.Alonso-CoelloP., . . . GRADE Working Group. (2008). GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. British Medical Journal, 26, 924–926.
27.
HigginsJ. P. T.GreenS. (2011a). How to include multiple groups from one study. In Cochrane handbook for systematic reviews of interventions (Version 5.1.0) [Internet]. The Cochrane Collaboration. Retrieved from https://handbook-5-1.cochrane.org/
28.
HigginsJ. P. T.GreenS. (2011b). Methods for incorporating cross-over trials into a meta-analysis. In Cochrane handbook for systematic reviews of interventions (Version 5.1.0) [Internet]. The Cochrane Collaboration. Retrieved from https://handbook-5-1.cochrane.org/
29.
HigginsJ. P. T.ThompsonS. G. (2002). Quantifying heterogeneity in a meta-analysis. Statistical Medicine, 21, 1539–1558.
30.
HirotaT.SchwartzS.CorrellC. U. (2014). Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: A systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. Journal of the American Academy of Child and Adolescent Psychiatry, 53, 153–173.
31.
IBM Corp. (2017). IBM SPSS Statistics for Windows (Version 25.0).
32.
KarimT. J.AkselC.KharasN.Reyes-VasquezC.DafnyN. (2018). Caudate nucleus neurons participate in methylphenidate function: Behavioral and neuronal recordings from freely behaving adolescent rats. Brain Research Bulletin, 142, 241–252.
33.
KharasN.Reyes-VazquezC.DafnyN. (2017). Locus coeruleus neuronal activity correlates with behavioral response to acute and chronic doses of methylphenidate (Ritalin) in adolescent rats. Journal of Neural Transmission, 124, 1239–1250.
34.
KodaK.AgoY.CongY.KitaY.TakumaK.MatsudaT. (2010). Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. Journal of Neurochemistry, 114, 259–270.
35.
MatthijssenA. M.DietrichA.BierensM.Kleine DetersR.van de Loo-NeusG. H. H.van den HoofdakkerB. J.. . . HoekstraP. J. (2019). Continued benefits of methylphenidate in ADHD after 2 years in clinical practice: A randomized placebo-controlled discontinuation study. American Journal of Psychiatry, 176(9), 754–762. https://doi.org/10.1176/appi.ajp.2019.18111296
National Collaborating Centre for Mental Health. (2009). Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults [NG72] [Internet]. British Psychological Society. http://www.nice.org.uk
38.
National Institute for Health and Care Excellence. (2018). Attention deficit hyperactivity disorder: Diagnosis and management [NG87] [Internet]. British Psychological Society. http://www.nice.org.uk
39.
NewcornJ. H.HarpinV.HussM.LyneA.SikiricaV.JohnsonM.. . . RobertsonB. (2016). Extended-release guanfacine hydrochloride in 6–17-year olds with ADHD: A randomised-withdrawal maintenance of efficacy study. Journal of Child Psychology and Psychiatry, 57, 717–728.
40.
OtasowieJ.CastellsX.EhimareU. P.SmithC. H. (2014). Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Systematic Reviews, 9, Article CD006997.
41.
PunjaS.ShamseerL.HartlingL.UrichukL.VandermeerB.NiklesJ.VohraS. (2016). Amphetamines for attention deficit hyperactivity disorder in children and adolescents. Cochrane Database Systematic Reviews, 2, Article CD009996.
42.
RieraM.CastellsX.TobiasA.CunillR.BlancoL.CapellàD. (2017). Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: Meta-analysis of 63 studies enrolling 11,788 patients. Psychopharmacology (Berlin), 234, 2657–2671.
43.
RobinsonT. E. (1984). Behavioral sensitization: Characterization of enduring changes in rotational behavior produced by intermittent injections of amphetamine in male and female rats. Psychopharmacology (Berlin), 84, 466–475.
44.
RossD. C.FischhoffJ.DavenportB. (2002). Treatment of ADHD when tolerance to methylphenidate develops. Psychiatric Services, 53, Article 102.
45.
SchwartzS.CorrellC. U. (2014). Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: Results from a comprehensive meta-analysis and metaregression. Journal of the American Academy of Child and Adolescent Psychiatry, 53, 174–187.
46.
SprosonE. J.ChantreyJ.HollisC.MarsdenC. A.FonelK. C. (2001). Effect of repeated methylphenidate administration on presynaptic dopamine and behavior in young adult rats. Journal of Psychopharmacology, 15, 67–75.
47.
StorebøO. J.KroghH. B.RamstadE.Moreira-MaiaC. R.HolmskovM.SkoogM.. . . GluudC. (2015). Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. British Medical Journal, 351, Article h5203. https://doi.org/10.1136/bmj.h5203
48.
SwansonJ.GuptaS.GuintaD.FlynnD.AglerD.LernerM.. . . WigalS. (1999). Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clinical Pharmacology and Therapeutics, 66, 295–305.
49.
ThomasR.SandersS.DoustJ.BellerE.GlasziouP. (2015). Prevalence of attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. Pediatrics, 135(4), e994–e1001.
50.
TurnerA. C.StramekA.KraevI.StewartM. G.OvertonP. G.DommettE. J. (2018). Repeated intermittent oral amphetamine administration results in locomotor tolerance not sensitization. Journal of Psychopharmacology, 32, 949–954.
51.
VolkowN. D.DingY. S.FowlerJ. S.WangG. J.LoganJ.GatleyJ. S.. . . HitzemannR. (1995). Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Archives of General Psychiatry, 52, 456–463.
52.
VolkowN.D.WangG.J.TomasiD.KollinsS.H.WigalT.L.NewcornJ.H. . . SwansonJ.M. (2012). Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. Journal of Neuroscience, 32, 841–849. doi:10.1523/JNEUROSCI.4461-11.2012
53.
WangG. J.VolkowN. D.WigalT.KollinsS. H.NewcornJ. H.TelangF.. . . SwansonJ. M. (2013). Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. PLOS ONE, 8, Article e63023.
54.
ZetterqvistJ.AshersonP.HalldnerL.LångströmN.LarssonH. (2013). Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: Total population study of trends and discontinuation patterns 2006–2009. Acta Psychiatrica Scandinavica, 128, 70–77. https://doi.org/10.1111/acps.12004
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
